Folgen
Shengqing (Stan) Gu
Shengqing (Stan) Gu
The University of Texas MD Anderson Cancer Center
Bestätigte E-Mail-Adresse bei mdanderson.org
Titel
Zitiert von
Zitiert von
Jahr
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
P Jiang*, S Gu*, D Pan*, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, ...
Nature medicine 24 (10), 1550-1558, 2018
36602018
Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism
N Levaot, O Voytyuk, I Dimitriou, F Sircoulomb, A Chandrakumar, ...
Cell 147 (6), 1324-1339, 2011
2062011
Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
SS Gu*, W Zhang*, X Wang*, P Jiang*, N Traugh, Z Li, C Meyer, B Stewig, ...
Cancer Discovery 11 (6), 1524-1541, 2021
1482021
Landscape of B cell immunity and related immune evasion in human cancers
X Hu, J Zhang, J Wang, J Fu, T Li, X Zheng, B Wang, S Gu, P Jiang, J Fan, ...
Nature genetics 51 (3), 560-567, 2019
1442019
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
X Wang*, C Tokheim*, SS Gu*, B Wang*, Q Tang, Y Li, N Traugh, Z Zeng, ...
Cell, 2021
1232021
Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer
C Wan, MP Keany, H Dong, LF Al-Alem, UM Pandya, S Lazo, K Boehnke, ...
Cancer research 81 (1), 158-173, 2021
1202021
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells
G Chan, LS Cheung, W Yang, M Milyavsky, AD Sanders, S Gu, WX Hong, ...
Blood, The Journal of the American Society of Hematology 117 (16), 4253-4261, 2011
1062011
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, W Alahmadi, ...
Nature communications 13 (1), 2559, 2022
1002022
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
Z Zeng, CJ Wong, L Yang, N Ouardaoui, D Li, W Zhang, S Gu, Y Zhang, ...
Nucleic acids research 50 (D1), D1391-D1397, 2022
762022
Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer
S Zhang, S Iyer, H Ran, I Dolgalev, S Gu, W Wei, CJR Foster, CA Loomis, ...
Cancer discovery 11 (2), 362-383, 2021
732021
Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants
X Wu, J Yin, J Simpson, KH Kim, S Gu, JH Hong, P Bayliss, PH Backx, ...
Molecular and cellular biology, 2012
572012
Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis
G Chan, S Gu, BG Neel
Blood, The Journal of the American Society of Hematology 121 (18), 3594-3598, 2013
562013
Immune receptor repertoires in pediatric and adult acute myeloid leukemia
J Zhang, X Hu, J Wang, AD Sahu, D Cohen, L Song, Z Ouyang, J Fan, ...
Genome medicine 11, 1-11, 2019
482019
SHP2 is required for BCR-ABL1-induced hematologic neoplasia
S Gu, A Sayad, G Chan, W Yang, Z Lu, C Virtanen, RA Van Etten, ...
Leukemia 32 (1), 203-213, 2018
452018
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
S Shi*, S Gu*, T Han, W Zhang, L Huang, Z Li, D Pan, J Fu, J Ge, M Brown, ...
Clinical Cancer Research 26 (22), 5990-6002, 2020
412020
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
BJ Aubrey, JA Cutler, W Bourgeois, KA Donovan, S Gu, C Hatton, ...
Nature cancer 3 (5), 595-613, 2022
312022
A molecular switch between mammalian MLL complexes dictates response to Menin–MLL inhibition
YM Soto-Feliciano, FJ Sánchez-Rivera, F Perner, DW Barrows, ...
Cancer discovery 13 (1), 146-169, 2023
302023
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1
S Gu*, WW Chan*, G Mohi*, J Rosenbaum, A Sayad, Z Lu, C Virtanen, ...
Blood, The Journal of the American Society of Hematology 127 (14), 1803-1813, 2016
302016
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
L Zhou, Z Zeng, AM Egloff, F Zhang, F Guo, KM Campbell, P Du, J Fu, ...
Journal for immunotherapy of cancer 10 (1), 2022
292022
CoBRA: containerized bioinformatics workflow for reproducible ChIP/ATAC-seq analysis
X Qiu, AS Feit, A Feiglin, Y Xie, N Kesten, L Taing, J Perkins, S Gu, Y Li, ...
Genomics, Proteomics and Bioinformatics 19 (4), 652-661, 2021
292021
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20